These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428 [TBL] [Abstract][Full Text] [Related]
8. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan. Hohenberger P; Bida B; Schlag PM Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039 [No Abstract] [Full Text] [Related]
9. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998 [TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147 [TBL] [Abstract][Full Text] [Related]
11. [Hyperthermic isolation perfusion of the extremities in malignant melanomas and soft tissue sarcomas]. Tonak J; Hohenberger W; Göhl J Chirurg; 1984 Aug; 55(8):499-504. PubMed ID: 6488994 [No Abstract] [Full Text] [Related]
12. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614 [TBL] [Abstract][Full Text] [Related]
13. Liposomal doxorubicin with and without TNFalpha in the perfusional treatment of advanced soft tissue limb sarcoma: preliminary results. Di Filippo F; Anzà M; Garinei R; Cavaliere F; Perri P; Botti C; Di Angelo P; Di Filippo S; Maini CL; Pasqualoni R; Di Segni S; Colantonio S; Bruno P; Piarulli L; Principi F In Vivo; 2006; 20(6A):735-8. PubMed ID: 17203757 [TBL] [Abstract][Full Text] [Related]
15. Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response. Hoving S; Seynhaeve AL; van Tiel ST; aan de Wiel-Ambagtsheer G; de Bruijn EA; Eggermont AM; ten Hagen TL Anticancer Drugs; 2006 Sep; 17(8):949-59. PubMed ID: 16940805 [TBL] [Abstract][Full Text] [Related]
16. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836 [TBL] [Abstract][Full Text] [Related]
17. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Plaat BE; Molenaar WM; Mastik MF; Koudstaal J; van den Berg E; Koops HS; Hoekstra HJ Clin Cancer Res; 1999 Jul; 5(7):1650-7. PubMed ID: 10430064 [TBL] [Abstract][Full Text] [Related]